Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.
Clin Infect Dis, 2010/5/01;50(9):1252-5.
Memoli MJ[1], Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK
Affiliations
PMID: 20345239DOI: 10.1086/651605
Impact factor: 20.999
Abstract
Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of clinically significant resistance to peramivir.
MeSH terms
Acids, Carbocyclic; Amino Acid Substitution; Antiviral Agents; Cyclopentanes; Drug Resistance, Viral; Female; Guanidines; Humans; Immunocompromised Host; Influenza A Virus, H1N1 Subtype; Influenza, Human; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Oseltamivir; RNA, Viral; Selection, Genetic; Sequence Analysis, DNA; Young Adult
More resources
Full text:
Europe PubMed Central; PubMed Central
EndNote: Download